April 2012 Drug Information Update - Pharmacy Benefits ...

More documents

Recommendations

Info

Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=572 Source: www.ashp.org Caffeine Citrate Injection and Oral Solution March 20, 2012 Products Affected - Description Caffeine citrate injection Cafcit injection, Bedford 20 mg/mL, 3 mL vial (NDC 22390-0357-03) Caffeine citrate oral solution Cafcit injection, Bedford 20 mg/mL oral solution, 3 mL vial (NDC 22390-0358-03) Reason for the Shortage • American Regent had temporarily suspended manufacture of most drug products in April, 2011. • American Regent resumed manufacturing in Shirley, New York in early-May, 2011. • APP had caffeine citrate on shortage due to increased demand. • Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes. • Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected, as well as the available products, listed on their website and are updating this information as it changes. • Paddock could not provide a reason for the shortage. • Caraco states the shortage was due to increased demand for product. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=862 Source: www.ashp.org Tobramycin Injection March 21, 2012 Products Affected - Description Tobramycin Solution for Injection, Akorn 40 mg/mL, 2 mL vial (NDC 23360-0014-02) - discontinued 40 mg/mL, 30 mL vial (NDC 23360-0014-30) - discontinued Tobramycin Solution for Injection, APP 10 mg/mL, 2 mL vial (NDC 63323-0305-02) Tobramycin Solution for Injection, Hospira 10 mg/mL, 2 mL vial (NDC 00409-3577-01) 40 mg/mL, 2 mL vial (NDC 00409-3578-01) 40 mg/mL, 50 mL vial (NDC 00409-3590-02) Tobramycin Solution for Injection, Teva 40 mg/mL, 2 mL vial (NDC 00703-9402-04) 40 mg/mL, 30 mL vial (NDC 00703-9416-01) Tobramycin Solution for Injection, Pfizer 40 mg/mL, 2 mL vial (NDC 00069-0088-02) 40 mg/mL, 30 mL vial (NDC 00069-0091-03) Reason for the Shortage • Teva has tobramycin solution for injection on shortage due to manufacturing delays. • Hospira has tobramycin on shortage due to increased demand for the product. 54
• APP had tobramycin 40 mg/mL presentation on shortage due to increased demand. • Pfizer acquired tobramycin injection from Akorn in early-May, 2011. • Pfizer states the reason for the shortage is manufacturing delay. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=701 Source: www.ashp.org Promethazine Injection March 21, 2012 Products Affected - Description Promethazine injection, West-Ward 25 mg/mL 1 mL ampule (NDC 00641-1495-35) 25 mg/mL 1 mL vial (NDC 00641-0928-25) 50 mg/mL 1 mL vial (NDC 00641-0929-25) 50 mg/mL 1 mL Novaplus vial (NDC 00641-0956-25) 25 mg/mL 1 mL Novaplus vial (NDC 00641-0955-25) 25 mg/mL 1 mL Novaplus ampule (NDC 00641-0948-35) 50 mg/mL 1 mL Novaplus ampule (NDC 00641-0949-35) Phenergan injection, West-Ward 25 mg/mL 1 mL vial (NDC 00641-6084-25) 50 mg/mL 1 mL vial (NDC 00641-6085-25) Promethazine injection, Hospira 25 mg/mL 1 mL Carpuject syringe (NDC 00409-2312-31) 25 mg/mL 1 mL iSecure syringe (NDC 00409-2312-02) - discontinued Promethazine injection, Teva 25 mg/mL 1 mL vial (NDC 00703-2191-04) 50 mg/mL 1 mL vial (NDC 00703-2201-04) Promethazine injection, X-Gen 25 mg/mL 1 mL ampule (NDC 39822-5500-03) Reason for the Shortage • Teva states the shortage is due to manufacturing delays. • West-Ward states the shortage is due to manufacturing delays. The company has also changed the NDC numbers for products that were formerly Baxter products. • Hospira has promethazine products on back order due to supply interruption. Hospira discontinued promethazine 25mg/mL 1 mL iSecure syringe in September 2011. • X-Gen could not provide a reason for the shortage. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=654 Source: www.ashp.org Potassium Chloride Injection March 21, 2012 Products Affected - Description Potassium chloride for Injection, APP 2 mEq/mL, 10 mEq/5 mL vials, package of 25 (NDC 63323-0965-05) 2 mEq/mL, 20 mEq/10 mL vials, package of 25 (NDC 63323-0965-10) 2 mEq/mL, 30 mEq/15 mL vials, package of 25 (NDC 63323-0965-15) 2 mEq/mL, 60 mEq/30 mL vials, package of 25 (NDC 63323-0967-30) Potassium chloride for injection, Hospira 2 mEq/mL, 10 mEq/5 mL vials, package of 25 (NDC 00409-6635-01) 55
Page 1 and 2:
April 2012 Drug Information Update
Page 3 and 4: First-Time Generics GENERIC DRUG NA
Page 5 and 6: GENERAL ANESTHETICS, INJECTABLE MID
Page 7 and 8: Gruenhaupt, Mark R.Ph. Argus Health
Page 9 and 10: Statin Drugs - Drug Safety Communic
Page 11 and 12: Vytorin (ezetimibe/simvastatin) Tab
Page 13 and 14: low blood sugar (hypoglycemia) in p
Page 15 and 16: Some women with depression who beco
Page 17 and 18: Survival increased for all groups o
Page 19 and 20: finding that it also may reduce the
Page 21 and 22: Syringes (2 mL size), Rx only. NDC
Page 23 and 24: Patheon Pharmaceuticals Inc., Cinci
Page 25 and 26: 50-ct. bottles (NDC 0067-6238-50);
Page 27 and 28: PRODUCT (Class II) 1) Ventolin HFA
Page 29 and 30: Lot #: 0693, Exp: 10/2012 RECALLING
Page 31 and 32: 24 (Display case UPC# 3030045074923
Page 33 and 34: CODE Lot # 139961 RECALLING FIRM/MA
Page 35 and 36: Reason for the Shortage • Teva co
Page 37 and 38: Reason for the Shortage • Ben Ven
Page 39 and 40: Products Affected - Description Gan
Page 41 and 42: 37.5 mg/25 mg, 1000 count (NDC 0078
Page 43 and 44: Acyclovir tablets, Major 400 tablet
Page 45 and 46: 500 mg, 100 count (NDC 63304-0726-0
Page 47 and 48: 750 mg tablets, 100 count (NDC 1013
Page 49 and 50: • Bedford Laboratories has multip
Page 51 and 52: Daunorubicin Hydrochloride Injectio
Page 53: Ciprofloxacin Immediate-Release Tab
Page 57 and 58: • Ben Venue voluntarily suspended
Page 59 and 60: 50 mg/mL, 10 mL vial, package of 10
Page 61 and 62: 2 mL vial, preservative-free (NDC 6
Page 63 and 64: 5 mg single dose vial, package of 1
Page 65 and 66: 20 mL glass ampule, sterile pack (N
Page 67 and 68: 2 mL iSecure syringe (NDC 00406-112
Page 69 and 70: Lidocaine 0.5% Xylocaine 0.5% injec
Page 71 and 72: • Teva discontinued all ciproflox
Page 73 and 74: Nicardipine hydrochloride injection
Page 75 and 76: Article link: http://www.ashp.org/D
Page 77 and 78: • Apotex had metformin products u
Page 79: • Covis purchased all rights to F
show all

April 2012 Drug Information Update - Pharmacy Benefits ...

Create successful ePaper yourself

Delete template?

Save as template?